fig1
![Patient-centric dose equivalency pilot study of incobotulinumtoxin a (xeomin) <i>vs</i>. abobotulinumtoxin a (dysport) in the treatment of glabellar frown lines](https://image.oaes.cc/e7f4601a-4259-4096-b0e2-ef6bda7af842/55.fig.1.png)
Figure 1. Neuromodulator dose ratio vs. muscle activity (percent) at 10-12 weeks
Figure 1. Neuromodulator dose ratio vs. muscle activity (percent) at 10-12 weeks
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/